<DOC>
	<DOCNO>NCT02155881</DOCNO>
	<brief_summary>The purpose study explore efficacy safety Ciclesonide Nasal Spray 200 microgram ( mcg ) daily treatment seasonal allergic rhinitis ( SAR ) Russian participant .</brief_summary>
	<brief_title>Efficacy Safety Ciclesonide Nasal Spray Participants With Seasonal Allergic Rhinitis ( SAR ) Russia</brief_title>
	<detailed_description>The drug test study call ciclesonide . Ciclesonide test treat allergy symptom people SAR . This study look improvement allergy symptom Russian participant take ciclesonide nasal spray . The study enroll approximately 80 participant . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed participant study doctor study ( unless urgent medical need ) : - Ciclesonide nasal spray 200 mcg - Placebo nasal spray ( dummy inactive nasal spray ) - nasal spray look like study drug active ingredient . All participant ask take 2 actuation per nostril time day throughout study , ask record severity allergy symptom twice day diary . This multi-centre trial conduct Russia . The overall time participate study 5 week . Participants make 3 visit clinic , contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>1 . Informed consent sign participant participation study . 2 . SAR male female participant age great equal ( &gt; = ) 18 year ( history SAR 2 year longer ) . In Investigator 's judgment SAR must sufficient severity require treatment ( either continuous intermittent ) period , expect require treatment duration study . 3 . To demonstrate positive skin prick test serologic test least 1 relevant seasonal allergen . A positive skin test generally define wheal 3 mm large diluent control wheal prick testing . 4 . If female less equal ( &lt; = ) 65 year age , must negative urine pregnancy test screening . Females childbearing potential must instruct agree avoid pregnancy study must use acceptable method birth control : 1 . An oral contraceptive , intrauterine device ( IUD ) , implantable contraceptive , transdermal injectable contraceptive least 1 month prior enter study continue use throughout study thirty day follow study participation ; 2 . Barrier method contraception , example ( eg ) , condom and/or diaphragm spermicide participate study . 1 . Nasal pathology , include nasal polyp , clinically relevant respiratory tract malformation , recent nasal biopsy ( within 60 day ) , nasal trauma , nasal surgery , atrophic rhinitis , rhinitis medicamentosa ( within 60 day ) , vasomotor rhinitis . 2 . Initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior Screening Visit AND use stable ( maintenance ) dose ( 30 day ) may consider inclusion . 3 . Hypersensitivity corticosteroid excipients formulation ciclesonide . 4 . A history respiratory tract infection disorder within 2 week screen visit respiratory tract infection baseline . 5 . Presence ocular herpes simplex cataract history glaucoma . 6 . Active asthma require treatment inhale systemic corticosteroid and/or routine use beta ( β ) agonists ; intermittent use βagonists acceptable . 7 . Use intranasal immunosuppressive drug 30 day Baseline . 8 . Female participant pregnant lactating . 9 . Participation investigational drug trial within 30 day precede Screening Visit plan participation another investigational drug trial time trial . 10 . History positive test human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C. 11 . History alcohol drug abuse within precede two year . 12 . Use prohibit concomitant medication within prescribe ( per protocol ) time spend last dose period Screening Visit ( Visit 0 ) entire treatment duration . 13 . Any condition , judgment investigator , clinically significant and/or affect participant 's ability participate clinical trial . 14 . Exposure systemic corticosteroid indication , chronic intermittent ( e.g . : contact dermatitis ) , past 2 month , presence underlying condition reasonably expect require treatment corticosteroid course study . 15 . Use topical corticosteroid concentration excess 1 percent ( % ) hydrocortisone dermatological condition past 1 month , presence underlying condition reasonably expect require treatment preparation course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>